Clover Biopharmaceuticals’ Phase I clinical data for its respiratory combination vaccine and RSV vaccine are positive.
October 15, 2025
Source: drugdu
78
On October 14, Clover Biopharmaceuticals (02197) announced positive data from Phase I clinical trials of its respiratory combination vaccine (RSV-hMPV-PIV3) and repeat RSV vaccine in the elderly population. Both Phase I clinical trials in Australia and the United States demonstrated favorable safety and immune responses.
Specifically, in the Australian trial, the mean doubling rates of RSV neutralizing antibodies induced by SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) were approximately 6-8 times, and the mean doubling rates of hMPV-A and hMPV-B neutralizing antibodies were 6-7 times and 8-9 times, respectively.
In repeat vaccination trials in the United States, heterologous repeat vaccinations of SCB-1019 (an RSV vaccine candidate) resulted in a mean RSV neutralizing antibody doubling rate of approximately 3.0-3.3 times. In contrast, homologous repeat vaccinations of AREXVY only boosted antibody levels to approximately 60-65% of the peak levels induced after the first dose. The company plans to advance SCB-1022 and SCB-1033 into Phase II clinical trials in the first half of 2026.
https://finance.eastmoney.com/a/202510143533731584.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
